Company Number: 14849400

Analysis Date: 2025-07-29 20:08 UTC

Financial Health Assessment Report for TROPHICELL LTD

---

1. Financial Health Score: D (Very Early Stage / Minimal Data)

Explanation:
TROPHICELL LTD is a newly incorporated micro-entity with minimal financial activity and limited financial data available. The company shows a very small asset base (£9 net assets) and nominal share capital (£8.50). With no revenues or profit/loss disclosed, and a micro-entity exemption from audit, the financial health score reflects an early-stage entity with undeveloped financial indicators. This score does not indicate distress but highlights the infancy of the company’s financial lifecycle.

---

2. Key Vital Signs

Metric	Value/Status	Interpretation
Company Age	~1 year (Incorporated May 2023)	Very early stage; financial track record not yet established
Account Category	Micro entity	Simplified reporting; limited financial disclosure
Net Assets	£9	Extremely minimal net worth; indicates limited financial resources
Share Capital	£8.50	Nominal capital invested, typical for start-ups
Current Assets	£9	Minimal short-term assets, likely cash or equivalents
Current Liabilities	£0	No immediate debts reported
Net Current Assets (Working Capital)	£9	Positive but negligible working capital; no liquidity concerns yet
Employees	4 (including directors)	Small workforce consistent with micro entity status
Audit Status	Exempt under section 477	Reflects micro-entity status; financial statements unaudited
Industry Classification	Biotechnology R&D and Pharmaceutical Manufacturing	High-risk, capital intensive, research-driven sectors; requires ongoing investment
Directors & Significant Control	5 directors; Principal shareholder owns 50-75%	Stable governance structure with expert leadership
Filing Status	Up to date	Compliance with filing deadlines reduces regulatory risk

---

3. Diagnosis: Underlying Business Health

TROPHICELL LTD presents the "vital signs" of a nascent biotech start-up in its embryonic phase of operation. The financial statements reveal very limited commercial activity, no recorded revenues or profits, and a net asset base of only £9. This suggests the company is in the research and development phase, consistent with its SIC codes related to biotechnology experimentation and pharmaceutical manufacturing.

The absence of liabilities indicates no current financial strain or debt burden; however, the minimal capital base signals that the company is likely dependent on external funding or investment for growth and ongoing operations.

The governance framework appears solid with qualified directors including a Chief Scientific Officer and Chief Executive, and a significant controlling shareholder with expertise (Professor Anthony Peter Hollander). The company complies with filing deadlines and maintains good administrative health.

The "symptoms" here are typical for an early-stage research-driven enterprise: minimal financial history, very low working capital, and no audit requirement. These are not signs of distress but rather the natural early life-cycle state, where operational viability depends heavily on successful R&D outcomes and future funding rounds.

---

4. Recommendations: Path to Financial Wellness

1. Capital Raising:
Given the minimal equity base, the company should focus on securing sufficient funding through grants, venture capital, or angel investment to finance R&D activities and operational expenses. Healthy cash flow will be critical to avoid liquidity "symptoms" such as inability to meet obligations.

2. Financial Planning and Controls:
Implement detailed budgeting and cash flow forecasting processes to monitor burn rate and funding runway. Early financial discipline will prevent surprises and support sustainable growth.

3. Progress Monitoring:
Develop key performance indicators (KPIs) linked to R&D milestones and commercialisation potential. These will act as "health metrics" to assess the company's progress toward financial viability.

4. Stakeholder Communication:
Maintain transparent reporting to investors and stakeholders to build trust and demonstrate prudent management of resources.

5. Prepare for Future Filings:
As the company grows beyond micro entity status, anticipate more comprehensive accounting and potential audit requirements. Early preparation will ease compliance burdens.

---

Executive Summary